TScan-II: A genome-scale platform for the de novo identification of CD4
CD4+ T cell
HIV
Pancreatic cancer
Sjögren’s disease
T cell epitope
T cell screening
antigen discovery
antigen library
epitope discovery
epitope mutagenesis
Journal
Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066
Informations de publication
Date de publication:
07 Dec 2023
07 Dec 2023
Historique:
received:
10
04
2023
revised:
12
07
2023
accepted:
25
10
2023
pubmed:
29
11
2023
medline:
29
11
2023
entrez:
28
11
2023
Statut:
ppublish
Résumé
CD4
Identifiants
pubmed: 38016469
pii: S0092-8674(23)01175-3
doi: 10.1016/j.cell.2023.10.024
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5569-5586.e21Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests M.H.D., T.K., and S.J.E. are patent holders of the TScan-I and TScan-II technologies. T.K. is a co-founder of TScan Therapeutics and ImmuneID and serves on the Scientific Advisory Board of TScan Therapeutics. S.J.E. is a founder of TScan Therapeutics, ImmuneID, MAZE Therapeutics, and Mirimus. S.J.E. serves on the Scientific Advisory Board of TScan Therapeutics and Maze Therapeutics. In accordance with Partners HealthCare's conflict of interest policies, the Partners Office for Interactions with Industry has reviewed S.J.E.’s financial interest in TScan and determined that it creates no significant risk to the welfare of the participants in this study or to the integrity of the research.